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ABSTRACT 
Irritable bowel syndrome (IBS) is the most common chronic functional gastrointestinal 
disorder that affects approximately 11% of the global population with a higher 
prevalence in women and those under the age of 50. IBS is characterized and 
diagnosed by the presence of a group of symptoms including abdominal pain, bloating or 
distension accompanied by altered bowel movements. A positive diagnosis of IBS can 
be made in the presence of well-defined, validated diagnostic criteria and in addition to 
the exclusion of organic disease with minimal testing. The lack of specific therapeutic 
targets makes treatment of IBS very difficult and its management is focused on symptom 
relief.  IBS has a well-established high comorbidity with anxiety, depression, and 
psychosomatic disorders which contributes significantly to a substantial burden of 
illness.  IBS patients exhibit a markedly decreased quality of life, decreased work 
productivity and increased absenteeism from work, and increased direct healthcare 
utilization (such as office visits, medical tests, and specialty referrals), resulting in a large 
economic burden for society. Despite this, effective pharmacologic and non-
pharmacologic treatment options are limited and many patients with IBS do not achieve 
complete symptom relief long term and continue to suffer from IBS symptoms.  
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Early pioneering in the study of this disease has called for a biopsychosocial model, a 
model in which psychological and social factors are also considered in IBS treatment. 
Through consideration of this model, it has been discovered that the disease has strong 
ties with early life environment, daily stress, and coping skills. Research in the past 
decades has established IBS as a disease of neurogastroenterology and involves 
disturbances in the brain-gut axis, the connection between the central nervous system 
and enteric nervous system. The brain-gut axis is organized in hierarchies with the first 
control level consisting of the enteric nervous system (ENS) sensory, muscular, and 
interneurons, all of which form reflex circuitry to control gastrointestinal (GI) motility and 
sensation among other functions. The central nervous system (CNS) synapses onto 
these circuits via vagal and spinal afferents. Information from the luminal GI tract is 
processed in the higher cortical structures of the brain, particularly in the hypothalamus, 
amygdala, anterior cingulage cortex (ACC) and prefrontal cortex (PFC). These 
structures are also important for homeostasis and regulation of attention, emotion, and 
behavior. Disturbances of these pathways result in peripheral and eventually central 
sensitization, the subject of this thesis. Sensitization in IBS includes visceral 
hypersensitivity, increased pain perception, and increased GI motility. Due to the cortical 
regions where this information is processed, these physical symptoms often have a 
complex interplay with psychological symptoms including anxiety, fear, and stress. The 
connection between the physical symptoms and psychological symptoms lies in the pain 
matrix and emotional motor system. This has been confirmed by many brain imaging 
studies comparing normal individuals with IBS patients testing visceral, somatic and 
cutaneous pain as well as anxiety and depression levels. IBS patients, unlike control 
subjects, have been found to have increased pain perception localizing to all these 
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regions and they also rate the pain as more unpleasant, a psychological factor, than 
normal patients. In addition to increased cortical activation, IBS patients have increased 
corticotropin releasing factor in the amygdala promoting anxiety and increasing stress 
levels and GI symptoms. Of note is the fact that stress is both a cause and effect of IBS 
symptoms and often compounds symptoms due to the cyclical nature of stress and 
chronic pain. Because stress ties in with both the physical and psychological symptoms 
faced by IBS patients, implementation of psychological treatment in IBS management is 
of great importance and have demonstrated improved outcomes in IBS patients. 
Psychological treatments with empirical evidence are discussed in this thesis and 
include cognitive behavioral therapy, psychodynamic psychotherapy, hypnotherapy, and 
mindfulness/relaxation exercises. Whether these all treatments tie into the alterations in 
cortical processing in brain-gut function is a topic that is yet to be explored. 
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INTRODUCTION 
 
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder 
(FGID) characterized by abdominal pain, bloating or distension along with altered 
bowel habits in the absence of discernable organic diseases. FGID are 
characterized by the absence of biomarkers that would allow for a straightforward 
clinical diagnosis using specific diagnostic testing; rather they are diagnosed and 
classified by the presence of certain clinical criteria and symptoms as most 
recently described in the Rome IV criteria (Lacy et al., 2016).  As such, these 
criteria help the clinician to make the diagnosis of a FGID more reliable. In 
contrast, organic diseases are those which are visible through diagnostic testing 
because of their distinct pathology; and are classified by organ morphology 
(Drossman, 2016).  
 
The estimated global prevalence of IBS is 11.2% with geographic variation; the 
lowest (7.0%) in South Asia and the highest (21.0%) in South America (Lovell 
and Ford, May 2012). Prevalence is higher in women than men by a difference of 
5.1%, with values of 14.0% and 8.9% respectively (Lovell and Ford, July 2012). 
Global prevalence also varies by age with a 25% higher prevalence in individuals 
over the age of 50 (Lovell and Ford, May 2012).  
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IBS represents one of several FGID and falls even further into the functional 
bowel disorder (FBD) classification, one of the six major classifications for FGIDs 
in adults  (Lacy et al, 2016). There are also pediatric categories of disorder based 
on age in which IBS can also fall into. FBD is broken up into five categories: 
irritable bowel syndrome, functional constipation, functional diarrhea, functional 
abdominal bloating/distension, and unspecified FBD. A new sixth category is 
opioid-induced constipation (OIC), which clinically manifests similar to functional 
constipation but can be generally attributed to the use of opioid-based pain 
therapy. In addition, due to significant overlap in symptoms, the different 
categories of FBD exist as a spectrum of disorders (Figure 1) making them 
difficult to distinguish between each other. As such, they should not necessarily 
be thought of as discrete disorders, merely a useful framework for researchers 
and clinicians (Lacy et al., 2016). For the diagnosis of IBS following the Rome IV 
criteria, the diagnostic criteria is  
“Recurrent abdominal pain, on average, ate least 1 day per week in the 
last three months, associated with two of the following criteria:  
1. Related to defecation 
2. Associated with a change in frequency of stool 
3. Associated with a change in form (appearance) of stool”  
(Lacy et al.,1394). 
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Figure 1. Conceptual framework to explain FBDs. These disorders should be 
considered as a continuum rather than as discrete disorders. Functional 
constipation (FC) or Functional diarrhea (FDr) are disorder with altered bowel 
movements alone (constipation or diarrhea, respectively, without the existence of 
abdominal pain. When altered bowel movements occur in conjunction with 
abdominal pain, the disorder is classified as IBS, which is further broken down 
into its subtypes. Abdominal bloating or distension often occur generally with any 
FBD. Figure taken from (Lacy et. al, 2016) 
 
It is important to note that IBS is a disorder in which both abdominal pain and 
altered bowel habits occur. Furthermore, IBS is broken down into four different 
subtypes based on the predominant type of bowel movement that the patient 
reportsshown in (Table 1.). The Bristol stool scale (Lacy et al., 2016) helps the 
clinician and patient to determine the predominant stool consistency. 
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IBS-C 
 
 
IBS with constipation 
• Hard or lumpy 
stools at least 
25% of the time 
• Loose or watery 
stools less than 
25% of the time 
 
 
IBS-D 
 
 
IBS with diarrhea  
• Loose or watery 
stools at least 
25% of the time 
• Hard or lumpy 
stools less than 
25% of the time  
 
 
IBS-M 
 
 
Mixed IBS 
• Hard or lumpy 
stools at least 
25% of the time  
• Loose or watery 
stools at least 
25% of the time  
 
 
IBS-U 
 
 
Unsubtyped IBS  
• Hard or lumpy 
stools less than 
25% of the time  
• Loose or watery 
stools less than 
25% of the time  
 
Table 1. IBS Subtypes and Diagnostic Criteria. Adapted from (NIDDK, 2015) 
 
 
Diagnostic criteria have assisted practicing clinicians greatly to make a positive 
diagnosis of IBS even though it may overlap or co-exist with other GI disorders, 
including other FGID. A positive diagnosis of IBS then facilitates the development 
of a rational treatment plan for the patient. Patients with IBS experience a great 
deal of substantial, yet variable GI symptoms that lower their quality of life 
tremendously and result in frequent doctor visits. To manage their predominant 
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symptoms treatment options are oriented towards lifestyle changes, such as 
dietary modifications, laxatives or anti-diarrheals, targeted pharmacological 
treatments, and sometimes psychological support. 
 
 
The Rome Foundation – Rome IV (May 2016) 
The Rome Foundation is a not for profit organization 
(http://theromefoundation.org/) established in the late 1980s to provide support 
for scientific research and education with the goal of improving current 
knowledge about FGIDs. This knowledge is useful for diagnosis and treatment in 
clinical practice as well as in research related to FGID. The Rome Foundation 
has periodically released compendiums of the gathered data for researchers and 
clinical practitioners to use. The latest compendium titled, Rome IV (Lacy et al., 
2016), was released in May 2016, ten years after the release of Rome III is the 
most recent reiteration of diagnostic criteria of FGID and the current 
understanding of their underlying biology. Much of the current knowledge about 
IBS can be attributed to The Rome Foundation, and the four Rome 
compendiums that have been released to date will be referenced to in this thesis 
extensively.  
 
 
The Biopsychosocial Model  
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In 1977, a breakthrough moment in medicine came through the reports published 
by Dr. Engel (Engel, 1977). Dr. Engel called for a revision in the current 
biomedical model of treatment of disease, arguing that it is reductionist and 
exclusionist because it requires that disease progression can only be 
conceptualized and defined by the biological defects in the patient. He continues 
with the notion that a physician’s role in treatment must include the realms of the 
biological, social, and psychological. Thus, he developed what is called the 
biopsychosocial model. Disease and medical care are interrelated through this 
model. He argues that “a medical model must also consider the patient, the 
social context in which he lives, and the complementary system devised by 
society to deal with disruptive effects of illness” (Engel, 1977). In disease, there 
are paradoxical states in which patients test positive for the biological defect but 
don’t feel sick, while other patients who feel very ill test negative for disease. Dr. 
Engel believes that a biopsychosocial model which is inclusive of both the illness 
and the patient would accommodate for both circumstances. 
 
The biopsychosocial model has been a helpful lens through which FGIDs, 
including IBS, can be viewed. Not only because FGIDs are symptom based 
conditions, but also because severity of symptoms, disease progression, 
treatment seeking behaviors, and treatment efficacy are so highly variable 
among individuals. There is no one unifying biochemical defect for IBS, but rather 
many potential defects and many compounding biological, social and 
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psychological factors which can contribute to the frequency and chronicity of the 
disease.  
 
Figure 2. Functional Gastrointestinal Disorders (FGID) – Conceptual Model. 
FGID manifests through symptoms and behavior that are caused by the 
combination of early life factors, genetics and environment; psychosocial factors 
in an individual’s daily life and the sudden changes in physiology. Additionally, 
the symptoms and behavior feedback the patients’ psychological well-being and 
social life and can compound the physiological effect and vice versa with the 
physiological sensation or somatization affecting the individuals psychology. As a 
result, individuals seek out medication, healthcare and their quality of life 
becomes impeded and daily function hindered. The frequent healthcare visits 
and decrease quality of life as well feeds back on psychosocial wellbeing and 
physiological symptoms in the individual. Figure adapted from (Drossman, 1999).  
 
 
 
Burden of Illness  
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It has been well-established that IBS lowers quality of life. In a study conducted 
in 2000, IBS patients in the US received lower Health Related Quality of Life 
(HRQOL) scores in all eight of the SF-36 categories; physical function, role 
limitations- physical, bodily pain, emotional well-being, role limitations- emotional, 
energy/fatigue, social functioning, and general health (Gralnek, 2000). Similar 
results have been obtained in populations in universities in the US and in Europe, 
further validating that IBS lowers quality of life.  
 
Figure 3. HRQOL Scores. Patients with IBS (black; n = 877) vs. general US 
population (white, n = 2474) in eight categories: PF- physical function, RP- role 
limitations physical, BP- bodily pain, EWB- emotional well-being, RE- role 
limitations emotional, EF- energy/fatigue, SF- social functioning, GH- general 
health. Figure adapted from (Gralnek, 2000)  
 
IBS also contributes significantly to high amount of health care expenditures. In 
2004, there were 3.1 million ambulatory care visits of patients with IBS as the 
diagnosis and an estimated 5.9 million prescriptions were filled at retail 
pharmacies (Everhart, 2009). Besides the large healthcare cost to the society at 
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large, IBS also interferes with work productivity as patients need to take sick 
days for their physician visits and to cope with their symptoms. IBS symptoms 
begin presenting most often in young adults, interfering with the lives of many 
individuals to launching their professional careers. When assessing the clinical 
determinants for why IBS lowers quality of life (QOL) almost universally among 
IBS patients, the findings indicated that QOL was lowered due to extraintestinal, 
systemic symptoms such as fatigue, low energy, feeling tense or nervous, low 
sexual interest, and “feeling that something is seriously wrong with their body.” 
Because of these findings, it is suggested that physicians try to focus more on 
global symptom severity and helping patients cope with anxiety and chronic 
stress that comes with the disorder (Spiegel, 2004). Due to the chronicity of the 
disease and often limited therapeutic success, along with the contribution of 
chronic stress and anxiety lowering QOL which also feed back on physiological 
factors, the relationship and trust between the healthcare provider and patient is 
of utmost importance and determines the therapeutic outcome in patients with 
IBS. Diagnostic evaluation of patients with suspected IBS can be generally 
minimal without invasive testing and is symptom oriented (Chey et al., 2015).  
However, because of the previous history with the debate on a biomedical model 
vs. a biopsychosocial model, providers tended to focus on the assessment of 
biomedical markers and exclusion of organic diseases which often involved 
unnecessary invasive testing or treatment modalities, such as colonoscopy and 
cholecystectomy (Chey et al., 2015). These failures to make a positive diagnosis 
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of IBS with minimal testing (which is possible using the Rome criteria) and 
manage symptoms may further frustrate patients and contribute to the stresses 
that decrease not only their mental HRQOL scores but also their physical ones. 
The development of a trusting provider patient relationship which makes a 
positive diagnosis of IBS, emphasizes the explanation of the natural history of 
IBS, and stating the realistic expectations of symptoms for patients often helps to 
avoid the use of invasive procedures and diagnostic examinations. It also avoids 
to a large degree the surmounting healthcare costs incurred by IBS patients. Due 
to the large interference in the daily lives of patients and the cost to the patient 
and the society as a whole, it is becoming increasingly important that health care 
providers find a way to help patients cope with their IBS symptoms based on a 
trusted relationship.  
 
   
Specific Aims 
Specific aims of this thesis include:  
• Characterization of the brain-gut axis hierarchical structure and 
neuroanatomy 
• Assessment of the changes to the brain-gut axis in IBS, specifically in the 
higher cortical regions with regards to increased sensitivity  
• Correlation between anxiety and stress with physical symptoms in IBS 
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• Analysis of studies conducting different types of psychological treatments 
as a treatment option and determining relative efficacy of each 
 12 
BRAIN-GUT AXIS  
A central feature in FGID that is becoming increasingly clear in recent years is an 
alteration to the brain-gut axis (BGA). The brain-gut axis is the connection 
between the central nervous system (CNS) and enteric nervous system (ENS), 
and includes communication via neural pathways including the autonomic 
nervous system (ANS), along with immune and endocrine messengers. Also, 
feeding into this pathway is the hypothalamic-pituitary-adrenal (HPA) axis. The 
basic hierarchy of the brain-gut axis is illustrated in figure 4 below.  
 
Figure 4. Neural control of the gut. There are four basic levels of integrative 
organization in the brain gut axis. Level 1 is the ENS acts locally. Level 2 include 
the prevertebral ganglia containing the postganglionic neurons that innervate the 
gut. Level 3 and 4 include the CNS with level 3 governing the ANS and higher 
cortical regions of the brain in level 4. Figure taken from (Wood et al., 1999). 
 
The centers of the brain that connect with the gut are also involved in body 
homeostasis and emotional regulation, thus stress has been implicated in being 
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a contributing factor towards IBS symptoms. Additionally, there is a high 
comorbidity rate of approximately 50% between IBS and common psychiatric 
illnesses including: major depressive disorder, generalized anxiety disorder, 
panic disorder, and posttraumatic stress disorder. Assessing dysfunction in the 
brain-gut axis is an important therapeutic target both pharmacologically and 
psychologically and has become a major focus in FGID research. Recent 
evidence also suggests cross-talk between the brain-gut axis and the gut 
microbiome via neuroimmune messengers secreted in the gut. In the following 
section, the neurological and neuroimmune pathways of the brain-gut axis will be 
discussed along with its effects on gut function and symptom perception. 
 
Neuroanatomy of Brain-Gut Axis 
The GI system itself has its own nervous system, the ENS, which has some 
functional similarities with the CNS, but also functions independently. Within the 
ENS there are sensory, motor, and interneurons that form local reflexes 
governing the behavior of gut musculature, secretory glands, and vasculature. 
Musculomotor neurons innervate the musculature and either inhibit or initiate 
contractile activity. Secretomotor neurons stimulate secretory glands to secrete 
chloride, bicarbonate, and mucus which maintain the pH and fluid contents of the 
gut lumen. Together this network determines motility (contractility) and enzyme 
and fluid secretion in the gut during various digestive and behavioral states (Lacy 
et al., 2016). Disruption of the intrinsic ENS circuitry may result in various 
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pathophysiological states. In addition to muscle cells, interstitial cells of Cajal 
(ICC) are also involved with the regulation of intestinal motility. ICC are non-
neuronal pacemaker cells that are connected to each other via electrical syncytial 
networks around the circumference and longitudinally through the myenteric 
stomach, small intestine, and large intestine (Takaki, 2003). They generate 
electrical pacemaker potentials resulting in spontaneous, rhythmic contractile 
activity in the gut which spread through gap junctions between the cells (Lacy et 
al., 2016). Sensory information is also relayed through these intrinsic circuits via 
ENS afferents and efferents. ENS afferents are referred to as EPANs (enteric 
primary afferent neurons) or IPANs (intrinsic primary afferent neurons). They 
respond to mechanical alterations of the mucosa and chemicals in the lumen 
along with radial stretch and muscle tension (Costa et al. 2000).  The various 
neurons of the ENS motor system are shown in the figure 5 below.  
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Figure 5. ENS circuitry. IPANS, sensory neurons of the ENS synapse with 
interneurons which process information and synapse onto musculomotor 
neurons. The musculomotor neurons innervate longitudinal and circular smooth 
muscle of the gut; mainly that of the myenteric stomach, small intestine and large 
intestine. Adapted from (Furness, 2012).  
 
Sensory information is relayed from the GI tract to the CNS via vagal and spinal 
afferents which are splanchnic and pelvic, respectively. The vagal nerve 
conducts largely sensory signals (information) such as presence of food, motor 
activity, and distension of the digestive track to the CNS (Mulak et al., 2004). 
Mechanisms by which this sensory information is relayed include 
mechanotransduction and luminal sensing (Lacy et al., 2016). Vagal efferents 
innervate the myenteric plexus. Previously, it was believed that the efferent 
neurons directly innervated the enteric motor neurons in the gut and all the 
information processing was mediated by the CNS. This classical model has been 
proven to be false in light of current evidence. It is now known that vagal 
efferents from the CNS synapse onto the integrative system of the ENS where 
information on reflexes are stored and information is processed. These 
interneurons then synapse onto enteric motor neurons and either inhibit or initiate 
contraction.  
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Figure 6. Classical vs. Current Model of Brain-Gut Pathways. In the classical 
model, vagal efferents synapse directly onto enteric motor neurons. In the current 
model, vagal efferents synapse onto the ENS integrative network of neurons 
which then give signals to enteric motor neurons. Figure taken from (Wood et al., 
1999).  
 
Sensory endings contain ion channels and receptors that convert various stimuli 
into action potentials. The ion channels are mechanosensitive and open or close 
in response to physical changes in the mucosal membrane. The receptors are 
both ionotropic and metabotropic and respond to messengers released by 
secondary sensory cells. These cells are in close proximity to the lumen and 
sense the luminal environment of the gut.  Cell types include ICC, enteric 
neurons, epithelial cells, enteroendocrine cells, mast cells and macrophages. 
 
The structures in the CNS that have been most significantly implicated in brain-
gut function include components of the limbic system: hypothalamus, amygdala, 
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anterior cingulate cortex (ACC) as well as the prefrontal cortex (PFC).  The major 
functions of these regions are shown in Table 2. 
Limbic Structure Functions Stimulus Response 
Hypothalamus • Govern CNS autonomic 
response  
•  Maintain homeostasis  
• Generate coordinated 
emotional response 
Emotional response- 
anger, fear, 
curiosity, lethargy, 
etc. 
Amygdala • Process emotions 
• Form emotional 
memories  
Changes in emotion 
and autonomic 
function  
Anterior Cingulate 
Cortex (ACC) 
• Integrate visceral, 
attentional, emotional 
information  
• Regulate affect  
Information 
processing; 
dispersal of pain 
inhibition signals 
Prefrontal Cortex 
(PFC) 
• Represent goals 
• Behaviors and vigilance 
to achieve goals  
• Process effect  
Increased vigilance; 
Affective processing  
 
Table 2. CNS Structures and Functions. Three of the regions in the limbic 
system- hypothalamus amygdala, and ACC along with its close connection to the 
PFC are the major relevant structures to FGID pathophysiology. Their major 
functions and response when stimulated are listed. Adapted from (Jones et al., 
2006). 
 
The limbic system is a region of the mammalian brain often referred to as the 
“visceral” or “emotional brain.” It functions to maintain homeostasis for the 
organism along mediating emotional responses (Tucker et al., 1995). Because 
this region of the brain regulates autonomic and neuroendocrine response and 
sensory perception, regulation of the gut and its pathophysiological states may 
be a result. The interconnection between the physical homeostasis and 
emotional motor system (EMS) suggests that emotions would also play a role in 
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GI pathophysiology. The limbic system is also closely connected to the PFC 
which is also involved with regulation and communication in the brain-gut axis. 
The PFC is involved in affective processing and its central role is to represent 
goals and behave in a way to achieve those goals (Jones et al., 2006). 
 
 
Figure 7. Inputs and Outputs of the Emotional Motor System (EMS). EMS, 
also known as the limbic system located in the CNS regulates peripheral body 
systems via autonomic, pain modulatory, and endocrine responses. These 
responses can act on the gut and form pathophysiological symptoms. EMS also 
signals to the forebrain (the prefrontal cortex) to modulate attention and 
emotional arousal. Input to EMS can be exteroceptive (psychological) or 
interoceptive (physical) stress. GI symptoms can exacerbate stress which further 
feeds into a pathological feedback loop. Figure taken from (Mayer et al., 2001). 
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Visceral Hypersensitivity and Pain Perception in Irritable Bowel Syndrome 
A hallmark feature in IBS patients is an increased perception of pain in response 
to visceral stimuli. This phenomenon is known as visceral hypersensitivity. Pain 
is a potent nonverbal signal prioritized by the CNS. Pain perception involves 
sensory, emotional and cognitive processing. Visceral pain is relayed to the 
spinal cord then brain via three pathways: spinothalamic, spinoreticular, and 
spinomesencephalic (Jones et. al 2006). These signals are then processed by a 
common network of cortical and subcortical regions referred to as the ‘pain 
matrix’. Regions of the pain matrix include: the mid/anterior insula, subregions of 
the ACC, PFC, thalamus, and occasionally the dorsal pons and periaqueductal 
gray (PAG). The pain matrix responds activates slightly differently to somatic and 
visceral pain (Chang et al., 2005). Two studies have demonstrated differences in 
somatosensory cortex activation between visceral rectal distension and somatic 
anal distension (Hobday et al., 2001 & Lotze et al., 1997). Both found greater 
activation of S1 cortex in somatic anal distension and the latter found increased 
motor cortex activation as well. Visceral rectal distension was associated with the 
same regions as somatic anal distension except in the study by Hobday et al., 
2001, ACC activation was only found in visceral stimulation. This however, differs 
from common knowledge that the ACC is activated in both somatic and visceral 
stimulation. An explanation for this could be that the visceral stimulation was non-
painful. However, the correlation between visceral pain and ACC activation is 
important to note. Another study showed that non-painful rectal distension 
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showed no activity in the ACC but when replaced with a painful stimulus ACC 
activation increased by 10.5% (Silverman et al., 1997). ACC activation increased 
as subjective pain intensity increased in normal individuals.  
 
Figure 8. Regional ACC Activity in Response to Perceived Intensity of 
Painful Stimuli. ACC was activated in anticipation of painful stimuli and 
activation increased in response to both actual and simulated stimulation. Linear 
regression of the relationship was statistically significant with a p-value < 0.01. 
Figure taken from (Silverman et al., 1997).  
 
In a comparison between noxious esophageal distension and cutaneous thermal 
stimulation, subject intensity did not differ. However, there was a marked 
difference in unpleasantness with the visceral esophageal pain rated more 
unpleasant (Strigo et al., 2000). These findings were further validated in another 
study where results demonstrated that when unpleasantness was matched in 
visceral and somatic stimulation, the intensity was lower with visceral stimulation 
(Dunckley et al, 2005). This shows that visceral pain has a psychological 
component as patients rated it more unpleasant even when pain intensity ratings 
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were lower. Somatic pain led to activation of regions involved with spatial 
orientation and exteroception such as the dorsolateral PFC and inferior parietal 
cortex. Visceral pain, on the other hand led to activation of the right anterior 
insula which is involved more with processing emotions and interoception 
(Dunckley et al., 2005). This suggests that processing of visceral pain results in a 
greater emotional and psychological response than somatic pain which is recruits 
the centers involved with spatial localization and motor response.  
 
 
Figure 9. Differences in Pain Intensity and Unpleasantness in Visceral vs. 
Cutaneous Stimulation. When matched for pain intensity, visceral stimulation 
was rated as more unpleasant. Figure taken from (Strigo et al., 2000).  
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Figure 10. Intensity and Unpleasantness in Painful Somatic (back and foot) 
vs. Visceral (Rectal) Stimulation. When matched for unpleasantness, physical 
pain intensity rating was much lower in rectal/visceral stimulation suggesting a 
psychological component to visceral pain. Figure taken from (Dunckley et al., 
2005).  
 
 
All three of the above-mentioned studies shared a significant feature in common, 
greater activation of the anterior/rostral portion of the ACC (Silverman et al., 
1997, Strigo et al., 2001, Dunckley et al., 2005). The anterior region of the ACC 
has been associated with attention. This region is also in close proximity and has 
connections with the rostral limbic system and PFC suggesting that an interplay 
between these regions is involved in affective pain processing (Devinsky et al., 
1995).  
 
Studies on patients with IBS have demonstrated lower pain thresholds, increased 
visceral hypersensitivity, and activation of regions of the brain involved with 
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emotions, especially linked with anxiety and fear responses. In a large study 
consisting of five different cohorts from different countries, similar results on 
increasing visceral hypersensitivity in conjunction with increasing GI symptoms 
were found across the board (Simren et al., 2017). Although other studies have 
showed opposite results with no or negative correlation between GI symptoms 
and sensitivity, those studies may be either not reproducible or had small sample 
sizes questioning the statistical validity of the results. In this study, only four of 
the five cohorts showed the same linear trend but with a p-value < 0.0001 
showing statistically robust significance, but do need further confirmation. In 
addition, IBS patients showed a significant negative linear relationship between 
symptom severity and pain threshold suggesting that IBS patients have a 
decreased pain tolerance. When controlling for visceral sensitivity, a significant 
relationship was found between GI symptom severity and anxiety or depression 
(Simren et al., 2017).  
 
Cohort Correlation Coefficient  p-value  
1 (n=242) -0.27 <0.0001 
2 (n=243) -0.20 0.002 
3 (n=159) -0.27 0.001 
4 (n=353) -0.29 <0.0001 
5 (n=147) -0.20 0.02 
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Table 3. Correlation Between Pain/Discomfort Thresholds and Z Scores of 
GI Symptom Severity in Five Patient Cohorts. A negative correlation between 
pain/discomfort threshold and GI symptom severity was found in the five different 
cohorts located in Belgium, the US, and Sweden. P-values of less than 0.05 were 
demonstrated in all five of cohorts. Adapted from (Simren et al., 2017).  
 
 
Another study demonstrated increased visceral and cutaneous sensitivity in IBS 
patients. Visceral sensitivity was examined using rectal distension and cutaneous 
sensitivity was tested using thermal stimulation. IBS patients rated visceral and 
cutaneous intensity as the same but rated visceral stimulation as more 
unpleasant (Verne et al., 2003). 
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Figure 11. Comparisons Between Control Group and IBS Group in Visceral 
and Cutaneous Pain Intensity and Unpleasantness. IBS patients reported a 
significantly higher pain intensity with both visceral (rectal) stimulation and 
cutaneous stimulation (to the foot). Both groups considered visceral stimulation 
as more unpleasant. IBS patients considered visceral stimulation to be much 
more unpleasant despite not considering it more intense. Figure taken from 
(Verne et al., 2003).  
 
 
When determining sensory thresholds between IBS patients, patients with 
abdominal pain of different causes, and healthy controls, IBS patients had a 
significantly lower pain threshold when compared to the control group and other 
FGID groups as well (Bouin et al., 2002).  
 
Figure 12. Rectal Pain Thresholds in Control vs IBS vs Groups with 
Abdominal Pain from Other Sources. IBS patients had a significantly lower 
pain threshold when compared to all the groups, even groups with other FGIDs. 
Figure taken from (Bouin et al., 2002).  
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Altered Pain Processing in Irritable Bowel Syndrome 
Current hypotheses to explain the increase in pain perception in IBS patients 
include an increase in afferent processing and increases in activation of certain 
cortical regions, and disturbances in pain inhibitory mechanisms. Although it has 
not yet been determined which mechanism is the initial cause of hypersensitivity, 
studies show slight differences in terms of activation of some regions, however, 
and further controlled testing need to be conducted. The two CNS regions that 
have been consistently found have increased activation in IBS patients in 
response to visceral pain are the dorsal ACC and insula. Other regions with 
increased activities include the thalamus, posterior cingulate cortex (PCC), 
somatosensory cortex (SSC), prefrontal cortex (PFC). IBS patients also have 
altered cerebral activity in response to anticipated but not actually received 
visceral stimulation, especially in subcortical regions with emotional processing 
function like the hypothalamus, amygdala and dorsal pons (Chang et al., 2005). 
The table below shows a summary of findings in previous publications. There are 
differences in data suggesting that CNS processing or cortical activity may not be 
the only cause of hypersensitivity, or that the etiology is heterogeneous. 
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Table 4. Summary of Brain Activity Findings in Control vs. IBS Patients 
Before and After Rectal Stimulation. There is a large variance in findings so it 
is difficult to make universal claims on brain activity and afferent processing in 
IBS and visceral pain. This area needs to be researched more. A possible reason 
for the heterogeneity is a host of other factors in the ENS that can disrupt neural 
processes. Table taken from (Jones et al., 2005).  
 
Three selected studies discussed had similar results using three different brain 
activity analysis techniques. In the study conducted by Verne et al., functional, 
structural, and angiographic images were acquired using a functional magnetic 
resonance imaging (fMRI) imaging technique to detect brain activity. Image slices 
were overlaid on top of each other to create a 3D anatomic image of the brain 
and areas of increased brain activity were highlighted.  
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Figure 13. 3D Anatomic Representation of Electrical Brain Scans in IBS 
Patients. Patients with IBS had an increase in brain activity in the ACC, PCC, 
PFC, and insula in both non-painful (35 mm Hg) and painful (55 mm Hg) rectal 
stimulation. Figure taken from (Verne et al., 2003).  
 
 
In this study, they also discovered that IBS patients had increased activation of 
the ventral posterior lateral (vpl) and dorsomedial (dm) thalamus, insula, SSC, 
and PFC in response to rectal stimulation. Another study using fMRI technique to 
record brain activity during rectal distension was conducted by Mertz et. al. 
Patients with IBS experienced greater activation of the ACC and insular cortex 
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(IC) during painful rectal distension than during nonpainful rectal distension. 
Compared to controls, IBS patients tended to have greater activation of the ACC 
and IC during painful stimulation as well (Mertz et al., 2001). The ACC has been 
implicated in forming memories with chronic pain and regulates arousal and 
attention providing an explanation as to why IBS patients have a such a marked 
sensitivity towards painful stimuli and why they find the stimulation to be so much 
more unpleasant (Wilder-Smith et al., 2004). 
 
Figure 14. Controls (A) vs IBS Patients (B) in Regional Brain Activity During 
Non-Painful (white and gray) and Painful (black) Rectal Distension. IBS 
patients had a significant increase in ACC and thalamic activity in response to 
painful stimulation over non-painful stimulation. There was also a trend towards 
greater activity in these regions in IBS patients vs. control, however the 
difference was marginally significant and the test should be repeated to validate 
the claim. Figure taken from (Mertz et al., 2000). 
 
 
In comparison to painful visceral stimulation, non-painful stimulation seems to 
activate different afferent pathways and results in differences in cortical activation 
as well. When comparing anticipated and received non-painful rectal distension 
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in IBS patients vs. control, IBS patients did not show an increased pattern of 
activity in the thalamus and PFC (Naliboff et al., 2001). Because these regions 
are involved with emotional and cognitive processing, the results suggest that the 
presence of visceral pain rather than visceral stimulation can result in increased 
pain perception. Activation of the rostral aspects of the ACC and the medial PFC 
is common in anticipation of aversive stimulation and has also been associated 
with increased activation in both normal and pathological anxiety (Drevets, 2001). 
Since IBS patients have greater activation of these regions in anticipation to pain, 
it can be theorized that at a resting state they are more anxious.  
 
Besides the increased activation of the pain matrix, IBS patients lack the ability to 
inhibit activated pathways and thus are not able to properly downregulate pain 
response. A study testing visceral and thermal cutaneous pain showed that IBS 
patients exhibit a decreased ability to modulate and downregulate pains when 
counter measures are performed to reduce pain intensity and unpleasantness. 
Counter-irritation in the form of a cold bath was used to help downregulate pain 
between thermal stimulations. The method of counter-irritation using an ice bath 
is an example of diffuse noxious inhibitory controls (DNIC).  IBS patients were 
found to not benefit from this and could not decrease pain intensity from thermal 
stimulation. There is also a correlation between visceral sensitivity and pain 
inhibition ability where a decreased visceral pain tolerance (visceral 
hypersensitivity) decreased the patients’ pain inhibitory function. (Piche et al., 
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2010). This suggests that pain inhibition is diminished broadly in IBS patients and 
the visceral hypersensitivity from the gut has caused a sensitization and the CNS 
level. Other studies have also demonstrated this diminished pain inhibition using 
visceral, cutaneous, and somatic stimulation as well (Song et al., 2006). 
Deficiency of DNIC mechanisms has been exhibited in various chronic pain 
states including chronic headaches, fibromyalgia, and IBS suggesting it to be an 
important area of research for FGID characterized by chronic pain and resulting 
in central sensitization (King et al., 2009).  
 
 
Figure 15. Control vs IBS Patients Modulation of Pain Intensity and 
Unpleasantness. IBS patients had a diminished ability to modulate both pain 
intensity and pain unpleasantness to a significant degree.  
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Figure 16. Thermal Sensitivity and Pain Inhibition. IBS patients showed 
increasing sensitivity to thermal pain in correlation to increasing levels of visceral 
hypersensitivity. A decreasing threshold of visceral pain resulted in a deficit in 
pain inhibitory mechanism suggesting a strong correlation between the disease 
state and altered CNS function.  
 
 
One mechanism by which the brain sends inhibitory efferent signals is via 
activation of the perigenual ACC (pACC). The pACC sends direct and indirect 
efferent signals via the amygdala to the ponto-medullary networks which include: 
the periaqueductal gray (PAG), rostral ventral medulla and raphe nuclei (Vogt et 
al, 1995). This decrease in pACC activity could be indicative of a diminished pain 
inhibition causing the increased pain response and visceral hypersensitivity. 
Abnormal modulation of pain was found in 70-85% of IBS patients and increasing 
clinical symptom intensity correlated with increasing abnormal modulation. 
Descending modulation is conducted by efferents through brainstem and spinal 
pathways and are modulated by cortical processes involved with cognition and 
emotion which further supports the idea that altered pain processing can be 
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attenuated by psychological circumstances (Wilder-Smith, 2011). Currently, few 
studies are available on brain imaging to provide a biological basis for decreased 
endogenous pain modulation in IBS patients, but given the consistent results 
showing IBS patients have altered endogenous pain modulation, this area can be 
very useful in gaining a better understanding of the correlation between altered 
cortical processing and IBS symptoms. 
 
Increased Anxiety and Fear Responses in Irritable Bowel Patients  
IBS patients have been found to have increased activation of the amygdala 
resulting in increased anxiety and fear in response to pain and symptoms. 
Psychological co-morbidities including anxiety and depression have been found 
to exacerbate symptoms in patients as well, creating a feedback loop between 
psychological health and physical IBS symptoms. Both treatment seeking and 
non-treatment seeking IBS patients have higher rates of clinically diagnosed 
anxiety disorder suggesting a strong link between the two disorders (Lydiard & 
Falsetti, 1999).  
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Figure 17. Brain-Gut Loop. GI distress modulates CNS function including 
increasing anxiety and fear which can then act on the gut and cause further gut 
dysfunction. Figure taken from (Lydiard & Falsetti, 1999).  
 
 
In a one year follow-up study, researchers found that subjects that did not have 
IBS but a high level of anxiety or depression had an increased incidence of IBS 
development in the one year follow-up. Similarly, the subjects who did have IBS 
had increased anxiety and depression levels in the one year follow-up (Koloski et 
al., 2016). This illustrates a strong association of anxiety/depression and IBS 
where one compounds the other and vice versa, albeit a causal relationship is 
possible but not proven. 
 
Table 5. Prediction of IBS at Follow-Up with Anxiety or Depression as a 
Predictor. Subjects with anxiety and depression who had no baseline FGID 
symptoms (negative) had a significantly higher chance of getting IBS at the one 
year follow-up. Table taken from (Koloski et al., 2016). 
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Table 6. Prediction of Anxiety or Depression at Follow-Up with IBS as a 
Predictor. Subjects with IBS had an increased likelihood of developing anxiety or 
depression at the one year follow-up. Table taken from (Koloski et al., 2016).  
 
 
IBS patients exhibited significantly higher anxiety (p <0.001) and fear (p < 0.004) 
in response to visceral pain than the control group. Between visceral and 
cutaneous stimulation, IBS patients reported much higher anxiety and fear over 
visceral pain than cutaneous despite rating the pain intensity equally in both 
(Verne et al., 2003). Not only visceral pain, but IBS patients also exhibited 
increased anxiety in response to thermal cutaneous pain (King et al., 2009).  
 
 
Figure 18. Pain, Anxiety, and Fear in IBS Patients During Visceral and 
Cutaneous Stimulation. IBS patients exhibited a markedly increased response 
to pain and unpleasantness during both visceral and thermal stimulation. They 
had increased anxiety and fear to both types of stimulation with especially high 
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levels of anxiety and fear during visceral stimulation. Figure taken from (Verne et 
al., 2003).  
 
 
The link between anxiety and IBS symptoms lies in the amygdala. IBS patients 
have higher resting-state functional connectivity (RSFC) of the amygdala with 
various connections in the brain. A study by Qi et al., 2016 found that IBS 
patients had a higher RSFC in amygdala-insula, amygdala-midbrain, amydgala-
para-hippocampal gyrus (PHG) and amygdala-sensorimotor regions. The insula, 
as mentioned previously is part of the pain matrix suggesting the amygdala has a 
role in increased pain. The amygdala-midbrain connection IBS patients has been 
implicated in processing of visceral information related to emotional stimuli 
suggesting a role in IBS patients’ increased pain perception. PHG is involved 
with coding long-term emotional memories suggesting that the negative emotions 
felt during visceral pain may be coded in IBS patients. The connection with 
sensorimotor regions illustrates that sensitization becomes widespread into the 
somatic and cutaneous domain suggesting widespread central sensitization (Qi 
et al., 2016). IBS patients have also demonstrated increased amygdala activity 
along with the pain matrix during rectal distension (Naliboff et al., 2003, Wilder-
Smith et al., 2004). These studies show that amygdala activity is both 
hyperactivated in IBS patients at a resting state and is also further hyperactivated 
during pain processing.  
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In an animal model, the amygdala was stimulated with stereotaxic delivery of 
corticosterone to determine its effects on the GI tract. It was revealed that the 
increased amygdala activity via corticosterone resulted in increased abdominal 
contractions in rats with nonsensitized and sensitized colons undergoing rectal 
distension (Greenwood-Van Meervald et al., 2001). 
 
 
 
Figure 19. Effect of Corticosterone (Activation of Amygdala) on Abdominal 
Contractions. The rats with nonsensitized colons are shown in the top two 
graphs while the ones with colons are illustrated in the bottom two graphs. Rectal 
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distension resulted in increased abdominal contractions in both types of subjects 
with administration of corticosterone having a significantly enhanced effect on 
motility. Figure taken from (Greenwood-Van Meerveld et al., 2001). 
 
 
These findings tie in with a previous study conducted by the same group that 
demonstrated that delivery of corticosterone to the amygdala also resulted in 
increased anxiety. Further evidence for the role of the amygdala comes from 
studies which show that increasing fear conditioning, an adaptive response 
facilitated by the amygdala, results in increased colonic sensitivity and motility. 
Fear conditioning was conducted on mice via electrical shock and cecocolonic 
spikes were measured to determine motility. The results demonstrated increased 
colonic motility (Gue et al., 1991). Another study of interest tested predictable vs. 
unpredictable odor shock in neonate mice and response to colorectal distension 
was measured in adulthood. Anxiety was assessed via light-dark emergence and 
the results showed longer emergence times indicating increased anxiety in the 
rats that received unpredictable shocks as pups. When neonates were exposed 
to unpredictable shocks (fear conditioning in early life), they showed increased 
sensitivity to rectal distension in adulthood (Tyler et al., 2007). This suggests that 
the anxiety induced by early life trauma leads to increased GI sensitivity in 
adulthood.  
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Figure 20. Abdominal Contractions During Colorectal Distension in Adult 
Rats with Unpaired (unpredictable) vs. Paired (predictable) Odor-Shock as 
Neonates. Unpaired odor-shock resulted in increased number of abdominal 
contractions indicating increased GI sensitivity in adulthood when exposed to 
early-life trauma. Figure taken from (Tyler et al., 2007). 
 
  
The amygdala facilitates both autonomic and endocrine responses to stress. One 
way this is done is through increasing corticotrophin releasing factor (CRF) 
expression and influencing the HPA to release adrenocorticotropic hormone 
(ACTH) and cortisol. The amygdala has also been linked to enteric functions 
such as gastric emptying and colonic motility. Overall, the role of the amygdala is 
wide and far-reaching with networks of projections reaching various brain regions 
including: PAG, raphe nuclei, parabrachial nucleus, locus coeruleus (LC), 
Barrington’s nucleus, etc., (Myers and Greenwood-Van Meervald, 2009). The 
proposed projections and effects on GI, pain, and anxiety are illustrated in the 
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figure below. Due to the large body of evidence regarding the link of anxiety with 
IBS symptoms and the evidence of increased amygdala activity facilitating this 
process, treatment modalities focusing on this aspect of the disorder should be 
considered for effective IBS management.  
 
  
Figure 21. Mechanisms for Amygdala-Mediated Integration of GI Motility, 
Nociception (Pain), and Anxiety. The amygdala contains a series of projections 
through various regions of the brain and facilitates activity via CRF, Glutamate, 
GABA, and other neurogenic molecules. CRF has been implicated in stress and 
IBS as well. Figure taken from (Myers and Greenwood-Van Meervald, 2009). 
 
 
 
Role of Stress in Irritable Bowel Syndrome  
Stress is known to play a large role in many chronic conditions. Stress is a 
physical, mental, or emotional factor that causes bodily or mental tension. 
Stressors can be either internal as result of illness or medical procedure or 
external from the environment and/or psychological and social situations 
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(http://www.medicinenet.com). Various studies have demonstrated that daily 
stress increases the intensity and severity of visceral pain (Moloney et al., 2016). 
A clinically relevant model demonstrated that three days of forced swim (FS) 
stress resulted in visceral hypersensitivity that lasted for months and IBS-like 
symptoms, mainly due to central sensitization. Additionally, this study showed 
that the combination of estrogen and FS stress produced significantly higher 
visceral hypersensitivity which may account for the female preponderance of IBS 
(Traub et al., 2014). It is generally accepted that stress disrupts the bi-directional 
communication between the brain and the gut via activation of homeostatic 
systems, particularly the HPA via release of CRF from the hypothalamus (Vanner 
et al., 2016).  
 
Figure 22. Effects of Stress on GI Function. Proposed mechanism of how 
stress can affect the bi-direction brain-gut axis. CRF from the CNS influences the 
mucosa, pain, visceral sensitivity, and smooth mucosal contractility. The mucosa 
and immune system in the gut can cause central sensitization and further 
compound symptoms. Figure taken from (Vanner et al., 2016). 
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In this model, a key mediator in stress-induced disruption of the brain-gut axis is 
CRF. The HPA axis is activated by stress and the hypothalamus releases CRF 
into the hypophyseal portal circulation where it reaches the anterior pituitary. The 
anterior pituitary releases adrenocortiocotrophin releasing hormone into the 
systemic circulation. ACTH travels through the bloodstream and reaches its 
receptors on the adrenal cortex which then releases glucocorticoid hormone, 
cortisol in humans and corticosterone in rats (Vanner et al., 2016).  Cortisol is a 
well-known hormone because of its role as the primary stress hormone. Its main 
function is to increase blood glucose, it increases the brain’s use of glucose, and 
increases availability of endogenous compounds important for tissue repair. 
Additional functions are to reduce nonessential functions during stressful or flight-
or-fight periods such as to alter immune response and suppress digestive, 
reproductive and growth processes. Cortisol also communicates with the brain to 
control motivation, fear and mood (Mayo Clinic Staff, 2016).  
 
As mentioned in the previous section, administering corticosterone to the 
amygdala of rats resulted in increased corticotrophin releasing hormone (CRH) 
expression. (CRH is another term for CRF). Another study conducted by Gue et 
al., involved a series of experiments on rats involving physical stress, 
administration of CRH and a CRH antagonist was used to evaluate the effects of 
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stress on visceral hypersensitivity. In the first experiment, results showed that 
abdominal contractions in response to colorectal distension (CRD) was increased 
in rats that had undergone partial resistant stress (PRS) compared to controls 
(Gue et al., 1991). The second set of experiments involved administering a CRH 
antagonist before subjecting the rats to PRS. The results showed that blocking 
CRH binding to its receptor via the antagonist decreased abdominal contractions 
from rectal distension compared to rats that did not receive the antagonist. The 
third set of experiments demonstrated increased abdominal contraction in 
response to rectal distension even in the absence of PRS, confirming the role of 
CRH in stress-induced visceral hypersensitivity (Gue et al., 1997). 
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Figure 23. Effects of Stress on Abdominal Contractions in Response to 
Rectal Distension (Visceral Hypersensitivity) Using Rats. Rats that were 
subjected to PRS had significantly higher number of abdominal contractions than 
controls (top left). When given alpha-CRH, a CRH antagonist before PRS the 
number of abdominal contractions decreased (top right). CRH administered 
without PRS had the same effect as PRS and rats had increased abdominal 
contractions with increasing dosage (bottom left). Figures taken from (Gue et al., 
1997). 
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Another study used daily water avoidance stress (WAS) in rats to determine the 
effects of chronic stress in visceromotor response (VMR). After 10 days of WAS, 
the rats had an increased VMR in response to CRD illustrating stress-induced 
visceral hypersensitivity (Bradesi et al. 2005).  
 
Figure 24. Visceromotor Response to CRD between Rats with chronic 10-
Day WAS Treatment vs. Control. VMR was increased in rats that went through 
10 days of WAS (A) compared to controls undergoing sham stress (B) providing 
further evidence that chronic stress increases visceral hypersensitivity.  Figure 
taken from (Bradesi et al., 2005). 
 
 
Experiments studying the effect of stress on the small bowel and colon have 
been conducted on humans as well and the results have mimicked typical IBS 
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symptoms. Psychological stress results in altered transit through GI in which 
mouth-to-cecum transit time was significantly faster in subjects exposed to stress 
by listening to a stressful recording (Cann et al., 983). CRH has been associated 
with peripheral GI functions such as delaying gastric and small intestinal (SI) 
emptying and increasing transit through the colon (Williams et al., 1987). 
Researchers found that administering CRH and immersion of hand into a cold 
water bath resulted in small intestine (SI) constriction and CRH caused the 
ascending colon (AC) to increase in volume. Overall, this results in faster transit 
from the SI to the colon where water is not absorbed fast enough causing 
diarrhea like patients with diarrhea-predominant IBS (IBS-D) (Pritchard et al, 
2015). Another study found the same results with SI constriction and AC volume 
after CRH was administered. It was also found that CRH resulted in fructose 
malabsorption but the reasons why remain still unclear (Murray et al., 2016).  
 
 
The effects of CRH on gastric and colonic motility are more pronounced in IBS 
patients. CRH administered to IBS patients resulted in greater descending colon 
motility than CRH administered to controls. 40% of IBS patients exhibited 
duodenal dysmotility. Abdominal symptoms resulting from CRH lasted longer in 
IBS patients and plasma ACTH levels were significantly higher (Fukudo et al., 
1998). 
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Figure 25.  Colonic Motility After Administering CRH in IBS Patients vs. 
Controls. CRH resulted in increased descending colonic motility in both groups 
and the effect was significantly greater in IBS patients. Figure taken from 
(Fukudo et al., 1998).  
 
 
Increased plasma ACTH levels are indicative of HPA axis dysregulation. IBS 
patients that demonstrated an exaggerated stress response illustrated via 
increased ACTH and cortisol levels following CRH infusion also had increased 
levels of pro-inflammatory cytokines IL-6 and IL-8. IL-6 is a potent HPA activator 
and increased levels in IBS patients could be a possible link to enhanced HPA 
responsiveness seen in these patients (Dinan et al., 2006). IL-6 and expression 
of its receptor in peripheral nerves, dorsal root ganglia, and the spinal cord, has 
also been shown to be increased during pain episodes (De Jongh et al., 2003) 
suggesting a possible role in IBS patients’ increased pain perception. These 
results further demonstrate the exaggerated stress response and resulting 
intestinal motility abnormalities and visceral hypersensitivity in IBS patients.  
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Figure 26. Increased ACTH and Cortisol Levels Following CRH Infusion in 
IBS Patients vs. Control. IBS patients had a significantly higher increase in 
ACTH (left) and cortisol (right) levels after CRH infusion compared to controls. 
Figures taken from (Dinan et al., 2006). 
 
 
In addition to increased visceral hypersensitivity and increased colonic transit, 
CRH has been implicated in increased intestinal permeability. CRH receptors 
type 1 and type 2 have been found in the ileum and colon.  Their ligand-specific 
activation results in increased intestinal permeability, mimicking the effects of 
stress and symptoms found typically in IBS patients (Larauche et al., 2009). IBS 
patients, specifically IBS-D patients, have increased intestinal permeability and 
this abnormality is even more pronounced in IBS patients without a prior history 
of gastrointestinal infection (Dunlop et al., 2006). Inflammation and altered 
mucosal permeability has been mainly associated with postinfectious-IBS 
(patients in which IBS occurs after a gastrointestinal infection; i.e. bowel habits 
never return back to a normal baseline) suggesting that nonpostinfectious-IBS 
patients have a similar underlying pathophysiology mechanism. Another study 
found the same results in all IBS patients when measured as lactulose/mannitol 
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ratios. Increased lactulose/mannitol ratios indicated the presence of increased 
intestinal permeability. This study also found that increasing intestinal 
permeability correlated with increasing symptom severity in IBS patients as 
determined by functional bowel disorder severity index (FBDSI) scores (Zhou et 
al., 2009).  
 
 
Figure 27. Increased Intestinal Permeability in IBS Patients. IBS patients 
have increased intestinal permeability in the small intestine demonstrated by the 
increased lactulose/mannitol ratios (left). Increasing intestinal permeability 
correlated with increasing severity of IBS symptoms using FBDSI score (right). 
Figures taken from (Zhou et al., 2009). 
 
 
IBS patients also exhibit an increased basal level of norepinephrine in the blood 
and exaggerated motor and sensory responses to controlled stress. These 
stressors include fear, aggression, unexpected environmental changes, social 
isolation, and other pathological conditions (O’Malley et al., 2011). In a study 
assessing stress mediator levels before, during, and after stress, IBS patients 
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demonstrated higher ratings for stress, a significant increase in CRH and ACTH 
levels during stress, and had an increased basal level of norepinephrine. The 
stress delivered to patients and controls in this study was acute mental stress via 
the Stroop test and the results illustrated the exaggerated neuroendocrine 
response found in IBS patients (Posserud et al., 2004). Another study found that 
urine catecholamines were higher both in the morning and afternoon in women 
with IBS, along with increased epinephrine and cortisol (Heitkemper et al., 1996).  
Increased cortisol levels have been found in female IBS patients in another 
study, especially upon waking in the morning, however other studies have 
showed conflicting results when taking into consideration patients who have 
undergone emotional abuse (Sugaya et al., 2015).   
 
Stress has very important implications in GI function in both healthy individuals 
and patients with IBS. IBS patients have often presented with stress axis 
dysfunction and exaggerated response to stress which have exacerbated their 
symptoms. Because stress is a daily part of life and unpredicted events are 
bound to occur in one’s lifetime, finding ways to cope are crucial in maintaining 
healthy gut function. Mechanisms of coping with stress should be incorporated 
into treatment plans for IBS patients stress can either cause or compound their 
symptoms and their symptoms can feedback and cause even greater stress, 
creating a harmful cycle. The table below summarizes stress-induced physiologic 
changes in IBS. 
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Function Findings in IBS vs. Controls 
GI Motility • Suppressed antral and small bowel motor activity and 
enhanced colonic motor activity  
Visceral Perception • Decreased rectal non-painful and pain thresholds to 
distension and electrostimulation during 
psychological stress in IBS but not controls 
• Higher stress, anxiety, and anger ratings in IBS vs. 
controls 
Intestinal 
Permeability and 
Secretion 
• Increased SI and colonic permeability demonstrated 
in IBS but not measured in response to stress  
• Net water flux significantly lower in healthy women 
with moderate stress compared to those with low 
stress 
• Chloride secretion was lower and albumin was higher 
in moderate stress vs. low stress but not statistically 
significant   
Autonomic Tone • Increases in blood pressure and heart rate shift to 
lower cardiosympathetic/vagal balance after mental 
stress in IBS and controls but no group differences  
HPA axis • Increased basal levels of cortisol in IBS vs. controls  
• Two studies show increased HPA axis response and 
one shows blunted response to hormone stimulation 
in IBS vs. controls 
• Most studies report lack of a response to a meal 
and/or mental stressor in IBS 
• HPA axis response varies depending on the type of 
physical stressor  
 
Table 7. Stress-Induced Differences in IBS vs. Controls. Results show 
variance between studies, but generally stress results in different body function 
and responses for IBS patients compared to controls. IBS patients have 
suppressed small bowel activity but enhanced colonic activity. They also have 
decreased pain thresholds to visceral pain, increased anxiety, stress, and anger, 
increased HPA axis activation, and increased basal cortisol levels. Table 
modified from (Chang, 2011).  
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EFFICACY OF PSYCHOLOGICAL TREATMENTS 
 
 
Due to the multifactorial underlying pathomechanisms in IBS, the role of stress, 
environmental factors, and co-morbidities with other disorders, the best clinical 
management of patients with IBS often involves multiple treatment modalities 
aiming to achieve symptom relief. Pharmacological treatment and dietary 
intervention often yield only partial symptom remission. Therefore, it is almost 
self-evident that treatment of a FGID such as IBS warrants a broad range of 
interventions, including specific management of the predominant GI symptoms 
(such as abdominal pain, bloating, and diarrhea or constipation) and a change in 
lifestyle and coping skills. Various treatment options now also include 
psychological interventions to supplement immediate symptom relief strategies. 
These improvements of patient care are hypothesized to be due to modulation of 
the stress response, ANS balance restoration, and changes in brain activation 
pattern in response to visceral stimuli (Koob and Heinrichs, 1999), though 
conclusive scientific evidence of this is currently limited. The three categories of 
psychotherapy with empirical evidence are: cognitive-behavioral therapy (CBT), 
psychodynamic therapy, and hypnotherapy (Blanchard et al., 2007). Other 
techniques include relaxation exercise and mindfulness meditation (Sinagra et 
al., 2012). Programs regarding long-term implementation of self-management 
have also been studied. Psychological interventions, at both cognitive and 
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behavioral level, have been found to increase symptom relief in both short-term 
and long-term follow ups, three months and one year respectively (Singara et al., 
2012). The following section will review the results of different psychotherapies 
observed in clinical trials.  
 
 
Cognitive-Behavioral Therapy  
Cognitive-behavioral therapy (CBT) has been proven to decrease IBS symptoms 
and improve the mental health of the IBS patient. It is the most studied of the 
psychotherapies for IBS. The CBT model involves the relationship between 
situations, thoughts, behaviors, physical reactions and emotions and patients 
learn to recognize the patterns and intervene when necessary. A visual 
representation of the model focused around IBS symptoms is shown in the figure 
below. 
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Figure 28. Hypothetical CBT Model for IBS Patient. The CBT model centers 
around the relationship between situations, thoughts, behaviors, physical 
reactions, and emotions. For an IBS patients, physical sensations may lead to 
avoiding social situations involving food causing isolation, embarrassment and 
shame. The stress induced by these thoughts and feelings may exacerbate 
symptoms. Figure taken from (Ballow & Keller, 2017). 
 
 
The CBT model for treating IBS has three major components: psychoeducation 
about the stress response and its relationship to GI symptoms, building insight 
into cognitive and behavioral responses to IBS symptoms and/or fear of 
symptoms, and modifying those responses to decrease distress related to IBS 
and physical reactivity to stress (Ballou & Keefer, 2017). 
 
An early study followed 25 IBS patients receiving CBT and 20 in the waiting list 
control group. The experimental group received eight 2-hour group sessions over 
a period of three months. These patients had significantly reduced abdominal 
complaints compared to the control group. In addition to GI symptom relief, 
patients in the treatment group had an increase in successful coping strategies 
and decrease in avoidance behavior. These outcomes were continued in long-
term follow-up averaging about 2.25 years later (van Dulmen et al., 1996). In 
another study with female FBD patients, CBT was found to be more effective 
than educational (EDU) sessions alone over a 12-week long period consisting of 
weekly hour long sessions with the same therapist (Drossman et al., 2003). 
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Figure 29. Outcome Score for CBT vs. EDU Group. CBT had significantly 
increased benefit compared to educational sessions alone with a p-value of 
0.001. Outcome score is a composite of four clinically relevant outcome 
variables: satisfaction with treatment, IBS-QOL, global well-being, and McGill 
Pain Questionnaire. Figure taken from (Drossman et al., 2003).  
 
 
When CBT is administered in addition to traditional pharmacological therapy, the 
effects were greater than pharmacological treatment alone. One study combined 
CBT with mebervine, an antispasmodic drug used to treat IBS. The combination 
therapy produced greater symptom relief with a reduction in total symptom 
severity scale (SSS) by 37 points and a decrease in global outcome score by 
14.4 points. This improvement persisted even six months after treatment, but the 
improvement was reduced after 12 months. Work and social adjustment 
improved with CBT as well, which continued 12 months after treatment (Kennedy 
et al., 2005).  
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Figure 30. Mean Scores on IBS Symptom Severity Scale. Treatment effect of 
CBT on total symptom severity scale and global outcome. CBT combined with 
mebervine produced greater symptom relief than mebervine alone, though the 
effects were less pronounced 12 months after treatment. Figure taken from 
(Kennedy et al., 2005).  
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Figure 31. Mean Scores on Work and Social Adjustments Scale. CBT 
reduced work and social adjustment scale score by 3.4 points over one year. The 
effect declined overtime but scores were still reduced at 12 months. Figure taken 
from (Kennedy et al., 2005). 
 
 
Due to the decline in efficacy, “booster” therapy sessions have been suggested 
to maintain initial improvement (Kennedy et al., 2005). These results were again 
replicated using the ROME-II scale to evaluate IBS symptom severity in a case 
study. IBS patients were separated into medical treatment alone and medical 
treatment plus CBT groups. The medical treatment consisted of loperamide, 
lomotil, dimethicon, metoclopramide, amitriptyline, which were prescribed by the 
patients’ gastroenterologists. Both groups were assessed by the ROME-II for IBS 
physical symptoms and the SCL-90-R questionnaire to evaluate mental health 
and psychological symptoms both pre- and post-treatment. The scores did not 
significantly differ pre-treatment, however at post-treatment, the intervention 
group showed significantly superior scores (p-value < 0.001). CBT administered 
alongside prescribed pharmacological treatments produced greater symptom 
relief and improved mental health in IBS patients, further validating the claim that 
combination therapy is more effective (Mahvi-Shirazi et al., 2012).  
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Table 8. Rome-II Questionnaire Scores Pre-Test and Post-Test. The case 
group is IBS patients receiving CBT and standard medical treatment while the 
control group is IBS patients receiving medical treatment alone. Scores were 
similar between the two groups pre-test and then were considerably reduced for 
the case group post-treatment showing statistically significant results at a p-value 
< 0.001. Table taken from (Mahvi-Shirazi et al., 2012).  
 
 
 
Although CBT has been proven to provide symptom relieve and improve the 
mental well-being of patients, it has thus far not shown demonstrable effects on 
the perception of pain. CBT does improve gastrointestinal, visceral and 
psychiatric symptoms but did not reduce the patients’ perception of pain in a 
recently conducted study using barostat measurements to determine actual and 
perceived rectal pain both with and without CBT. This seems to suggest that the 
effect of CBT is more central rather than a direct alteration of visceral afferents of 
the gut. Symptom relief arises most likely from improved psychological coping by 
the patients, which in turn results in reduced stress (Edebol-Carlman et al., 
2017), a factor that has been implicated in central sensitization as discussed in 
the previous section.  
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Psychodynamic Psychotherapy   
Psychodynamic psychotherapy is an umbrella term for treatment modalities that 
operate on a continuum of supportive-interpretive psychotherapeutic 
interventions. Interpretive interventions aim to enhance patient insight into 
repetitive conflicts contributing to patients’ problems. Supportive interventions 
aim to strengthen the abilities inaccessible to patients due to stress or that have 
not developed sufficiently in their lifetime (Leichsenring & Leibing, 2007). The 
most interpretive is insight-enhancing interpretation while the most supportive 
techniques include advice, praise, and affirmation. Falling in the middle of the 
spectrum are confrontation, clarification, and empathic validation (Leichsenring et 
al., 2006). Psychodynamic therapy also includes interpersonal therapy, a type of 
therapy geared towards helping individuals solve dilemmas or problems in their 
relationships and family life. When assessing psychodynamic therapy specifically 
in the realm of interpersonal problems, researchers found that interpersonal 
problems led to longer disease durations, and change in interpersonal problems 
led to change in pain mediated by changes in psychological distress. Change in 
interpersonal problems was a predictor of improved health status in a long-term 
(fifteen-month) follow up (Hyphantis et al., 2009).   
 
With respect to IBS, the aim of psychodynamic psychotherapy is to help the 
patient identify problem areas in their relationships and understand how it affects 
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their bowel movements. As a result, the patient is helped to make changes to 
improve emotional status and relationships (Guthrie & Whorwell). There are 
relatively few studies with data on psychodynamic therapy, but those few contain 
convincing data on efficacy in IBS symptom management and mental health. The 
first study to test the effects of psychotherapy on IBS patients was conducted by 
Svedland et al., 1983. 101 patients received medical therapy with or without 
psychotherapy for a period of three months. During the treatment period, 
symptom improvement was greater in the group that received psychotherapy 
along with medical treatment compared to the control group which received only 
medical treatment. In a one year follow-up, improvement continued in the 
psychotherapy group while symptoms recurred in the control group back to the 
pre-treatment initial state (Svedland et al., 1983). Another study by Guthrie et al., 
1991 confirmed these results with a similar sized sample group of 102 IBS 
patients. 53 were placed in the treatment group and 49 in the control. There were 
no significant differences between the two groups in terms of age, social class, 
marital status, severity or duration of IBS, and proportion with psychiatric 
diagnoses. All the patients had received six months of standard medical 
treatment prior to the beginning of the study which they continued during the 
study. The experimental treatment group received dynamic psychotherapy where 
their bowel and psychiatric symptoms were assessed and their feelings about the 
illness and emotional problems were explored. They had one initial interview 
followed by six follow-ups and received a relaxation tape to use regularly at 
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home. At three months, the treatment group displayed a significantly improved 
total severity score for their IBS symptoms, and their own rating of their 
symptoms showed significant improvement as well. The treatment group also 
exhibited significantly improved anxiety and depression scores and changes in 
psychiatric symptoms were highly correlated with changes in bowel scores. 
These improvements were maintained even at a one year follow-up. Psychiatric 
treatment was also associated with a significant decrease in outpatient visits 
during that year.  
 
An interesting discovery in this study was that patients who were aware of stress 
or psychiatric symptoms relating to their pain showed symptom improvement. 
These patients have discernable episodes of pain and when they recognized 
these episodes were caused by stress, anxiety or depression, were amenable to 
improvement via psychiatric treatment. On the other hand, patients who received 
psychiatric treatment but had chronic pain with no discernable episodes did not 
show improvement (Guthrie et al., 1991). This seems to suggest that an 
awareness of psychology and its effect on body functions plays an important role 
in a chronic condition with a pain component such as IBS. This represents a 
clinical manifestation of concepts explored in the previous section and provides 
further evidence regarding the benefits of psychiatric treatment modalities and 
educating patients on coping skills.  
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Hypnotherapy 
Hypnotherapy involves the induction of the patient into a state of relaxation or 
trance and then making suggestions on improvement in their condition. Gut-
directed hypnotherapy (GHT) is a specific type of therapy aimed at normalizing 
gastrointestinal function. The first two sessions are geared towards getting the 
patient acquainted with the hypnosis process. Focus on the gut is introduced 
from the third session onward and patients receive audios to take home and 
practice with (Whorwell, 2005). Treatment usually lasts for 7-12 sessions in 
which patients are led through scripted gut-focused imageries and hypnotic 
suggestions in each session (Ballou & Keefer, 2017). There are currently two 
standardized hypnotherapy protocols: the Manchester approach (Gonsalkorale, 
2006) and the North Carolina approach (Palsson, 2006), which last twelve and 
seven weeks, respectively.  
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Figure 32. Gut-Directed Hypnotherapy. The first two sessions involve 
educating and assisting the patient with the hypnotherapy process and inducing 
a hypnotic state. The next sessions involve induction and deepening of the 
hypnotic state followed by scripted gut-directed suggestions and finally a 
transition to wakeful awareness. Figure taken from (Ballou & Keefer, 2017). 
 
 
GHT has been shown to be effective in IBS treatment. A systematic review of 
literature regarding hypnotherapy use in IBS treatment from 1970 to 2005 
showed that all studies that met inclusion criteria demonstrated improvement in 
of all major IBS symptoms, extra-colonic symptoms, quality of life, anxiety and 
depression (Gholamrezaei et al., 2006). The first controlled study testing 
hypnotherapy on IBS was conducted in 1984 by Whorwell’s group. 30 patients 
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with severe refractory IBS were placed into groups with either hypnotherapy, 
psychotherapy, or placebo. Psychotherapy patients showed a small but 
significant improvement in abdominal pain, distension, and general well-being. 
Hypnotherapy patients showed a dramatic improvement in the same categories 
and additionally in bowel habits. These improvements lasted into the three-month 
follow-up without relapse (Whorwell et al., 1984). A follow-up study by the same 
group seems to suggest, however, that hypnotherapy is more effective for 
specific sub-groups of patients with IBS including those under the age of 50 and 
those with more classical cases of IBS (Whorwell et al., 1987). When assessing 
the durability of hypnotherapy as a treatment option it was found that its positive 
effects, including IBS symptom scores and extra-colonic symptoms, decrease 
anxiety and increase quality of life, lasted up to 5 years (Gonsalkorale et al., 
2003).  
 
Table 9. Overall IBS Scores for Responders According to Time Lapsed 
After Treatment. IBS symptom severity scores were significantly diminished in 
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1, 2, 3, 4, and 5+ years after hypnotherapy treatment. Figure taken from 
(Gonsalkorale et al., 2003).  
 
 
Furthermore, a large study of 1000 adult patients provided further evidence of the 
effectiveness of hypnotherapy in patients with treatment-refractory IBS. Again, 
the improvement in IBS symptom severity scores, non-colonic symptom scores 
and quality of life were replicated. Anxiety and depression scores fell after 
hypnotherapy as well. The overall scores in each category showed significant 
improvement as well as each of the sub-categories shown in figure 32. Overall, 
all sub-groups showed significant improvements, whereby improvement was 
preferentially observed in female patients and those patients with anxiety. The 
improvement of symptoms in patients with anxiety suggests (by the authors) that 
the mechanism by which hypnotherapy improves IBS symptoms is psychological 
(Miller et al., 2015).  
 
Figure 33. IBS Symptom Severity Score and Overall Non-Colonic Score Pre- 
and Post-Hypnotherapy. IBS score and non-colonic score significantly 
decreased following hypnotherapy with p-values <0.001. Each of the individual 
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subcategories in overall IBS symptom score and non-colonic score had 
significant decrease as well.  
 
 
Figure 34. Quality of Life Score Pre- and Post-Hypnotherapy. Overall quality 
of life increased significantly with a p-value < 0.001. The subcategories of the 
quality of life questionnaire also exhibited significant improvement.  
 
 
More standardized studies have been conducted comparing the efficacy of 
standard medical treatment (SMT) alone vs. standard medical treatment 
combined with GHT in terms of quality of life. Immediately following treatment, 
60.8% of the GHT + SMT group improved while 40.9% of the SMT only group 
improved. In a 15 month follow-up the difference was even greater with 54.3% of 
GHT + SMT showing improvement vs. 25% of SMT alone. SMT, when 
supplemented with GHT, has a more robust effect on quality of life improvement 
as well as a more long-lasting one (Moser et al., 2013). The significant effect of 
 67 
GHT on psychological well-being seems to suggest a psychological mechanism 
involved. Another study conducted by Whorwell’s group assessed the effect of 
hypnotherapy on emotional and physiological responses. Hypnotic induction of 
three emotional states, excitement, anger and happiness were compared with 
resulting changes in colonic motility. Out of the three, happiness decreased 
colonic motility while anger and excitement increased colonic motility. Hypnosis 
alone decreased colonic motility and a decrease in colonic motility was 
accompanied by decreased pulse and respiratory rate. This demonstrates the 
importance of positive emotions on gut symptoms and the way in which hypnosis 
can be used as treatment (Whorwell et al., 1992).  
 
Figure 35. Distal Colonic Motility Before and After Hypnosis and During 
Hypnotic Induction of Three Emotional States. Hypnosis on its own 
decreased colonic motility while induction of excitement and anger increased 
colonic motility. Hypnotic induction of happiness decreased colonic motility to its 
lowest point. Figure taken from (Whorwell et al., 1992).  
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Further studies have attempted to demonstrate the direct effect of hypnosis on 
symptoms associated with IBS. An initial study compared the effect of 
hypnotherapy on disordered rectal sensitivity threshold in IBS patients. The study 
consisted of ten hypersensitive patients, seven hyposensitive patients, and six 
normal sensitivity patients. The hypersensitive patients exhibited an increased 
pain threshold in response to hypnotherapy compared with lower than standard 
threshold levels prior to therapy. Similarly, hyposensitive patients with a higher 
than normal pain threshold exhibited decreased pain threshold after 
hypnotherapy, albeit with lower significance than the hypersensitive group. The 
normal group remained unchanged. These results suggest that hypnotherapy 
plays a role in normalizing abnormal pain threshold and perception in IBS 
patients (Lea et al., 2003).   
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Figure 36. Pain Thresholds Before and After GHT. Pain thresholds were lower 
than standard in hypersensitive patients and following GHT increased back within 
a normal range with a p-value < 0.04. Pain thresholds were higher than standard 
in hyposensitive patients and declined to normal range levels after GHT with a p-
value 0.19 (less significant than with hypersensitive patients. GHT did not  
change pain thresholds in already normal sensitivity patients. Figure taken from 
(Lea et al., 2003). 
 
 
As increased rectal sensitivity is a hallmark of IBS and central sensitization, 
studies have been conducted to assess the effects of hypnotherapy on central 
processing of pain. In a study assessing cortical region activation, subjects were 
split into three groups: hypnotherapy, education, and healthy controls. Compared 
to healthy controls, the IBS patients had higher activation of the PFC, 
midcingulage cortex (MCC) and ACC. The patients who responded to either 
treatment, both hypnotherapy and education, had decreased activation of these 
regions during rectal distension.  When comparing the hypnosis responders vs. 
the education responders, those who received hypnosis showed decreased 
activation of the anterior insula and the posterior insula when hypnosis 
responders were compared with healthy controls. This decreased activation is 
consistent with reduced spinal afferent input to the brain. The observed decrease 
was not different during the different distensions suggesting a change in central 
processing rather than a visceral change (Mats B.O. et al., 2013).  
 
Overall, the three psychological therapies discussed have universally affected 
IBS symptoms and quality of life positively. Further research may be needed to 
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standardize these results as there are many compounding variables and 
limitations to the studies. Additionally, it may be of importance to search for a link 
between psychological treatment and physiological changes, a field that is 
currently lacking in studies and data. Although CBT is the most widely 
researched therapy for IBS, there is limited data on whether CBT has a 
physiological effect. Psychodynamic psychotherapy has the least studies of the 
three and needs further investigation. Interpersonal psychodynamic therapy, 
though, has provided a link between personal distress in relationships and more 
sever IBS symptoms. Hypnotherapy produced many consistent results including 
changes in central processing, and provides a link between emotions and GI 
symptoms. However, there still exists a mysticism surrounding hypnotherapy and 
this may be a barrier that needs to be broken down.  
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CONCLUSION 
 
Understanding the brain-gut axis is crucial to learning more about the underlying 
mechanisms of IBS. Increased visceral sensitivity and pain perception are 
hallmark features of functional gastrointestinal disorder and reduction of these 
symptoms may be an important target of potential symptom relief. The cortical 
regions of the pain matrix are closely tied to emotional regulation and body 
homeostasis. There is repeated evidence of increased anxiety, fear, depression 
and stress associated with increased IBS symptoms. The biopsychosocial model 
suggests that these events are interrelated and cyclical in nature with one 
causing the other and vice versa. As such it is crucial to find ways to regulate 
psychological symptoms in order to alleviate the physical symptoms. 
Psychological treatment of patients with IBS has been shown to provide 
symptom relief in the short and long term, both in the realms of IBS symptom 
severity and mental health scores.  One link that has yet to be established, 
however, is the link between altered cortical processing and psychological 
symptoms. Further evidence for the efficacy of psychological treatment may 
come in this form. When IBS symptoms are improved, the pain matrix will return 
to a less hyperactive state. Whether psychological treatment can cause this 
physiological response is yet to be determined. Future research should focus on 
this question as it will provide even more convincing data for the efficacy of 
psychological treatment. Another area of interest is treatment delivery via the 
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internet. Psychological treatments are now being delivered through internet-
based therapy. White this delivery method has been initially tested for efficacy in 
IBS treatment future clinical trials are needed to firmly establish this novel 
modality as routine treatment. As technology progresses further, internet-based 
psychotherapy may become a preferred method of treatment for many patients 
as it saves time and travel expense. Determining if internet-delivery of 
psychological treatments have the same effect on IBS symptom relief is another 
broad realm for further research.  
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